Jubilant Pharmova (NSE:JUBLPHARMA) Net Income From Continuing Operations : ₹8,363 Mil (TTM As of Mar. 2025)

View and export this data going back to 2003. Start your Free Trial

What is Jubilant Pharmova Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Jubilant Pharmova's net income from continuing operations for the three months ended in Mar. 2025 was ₹1,513 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was ₹8,363 Mil.

Jubilant Pharmova Net Income From Continuing Operations Historical Data

The historical data trend for Jubilant Pharmova's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jubilant Pharmova Net Income From Continuing Operations Chart

Jubilant Pharmova Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Net Income From Continuing Operations

Get a 7-Day Free Trial

12,120.10

6,304.47

278.00

1,705.00

9,806.00

Jubilant Pharmova Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Income From Continuing Operations	Get a 7-Day Free Trial															-618.00	4,818.00	1,025.00	1,007.00	1,513.00

Jubilant Pharmova Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹8,363 Mil.

Jubilant Pharmova Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jubilant Pharmova Ltd (NSE:JUBLPHARMA) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

530019:India

Address

1A, Sector 16A, Noida, UP, IND, 201301

Website

https://www.jubilantpharmova.com

Jubilant Pharmova Ltd is an integrated pharmaceutical company. The company operates in the following segments; Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation; and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment which specializes in developing, manufacturing, commercializing, and distributing therapeutic agents in the nuclear medicine domain. Geographically, it derives a majority of its revenue from the Americas and Europe and the rest from India and the Rest of the world.

Jubilant Pharmova Headlines

No Headlines